J L Morison Sons & Jones (Ceylon) PLCMORI.N0000:CSE

275.00
5.00 / 1.79%
17
22.54%
1.60
Close in LKRToday's changeShares traded1 year changeBeta
Data delayed at least 20 minutes, as of Jul 31 2014 08:03 BST.

About the company

3.08bn156.09m2007--
Revenue in LKR (TTM)Net income in LKRIncorporatedEmployees
IndustryMajor DrugsLocation
J L Morison Sons & Jones (Ceylon) PLC
No. 618, 620, Biyagama Road
Pethiyagoda, Kelaniya.
COLOMBO
Sri Lanka
LKA
J.L. Morison Son & Jones (Ceylon) PLC is a Sri Lanka-based company primarily engaged in the manufacture of pharmaceuticals and toiletry products and the import and distribution of finished pharmaceuticals, toiletries, agro chemicals, medical aid and other consumer products. The Company's business segments comprise manufacturing and trading, promotional activities, hotel industry, wharf clearing activities, and transport service. Together with its subsidiaries, the Company is engaged in the importing and distribution of pharmaceuticals, agro chemicals, medical aid, household insecticides, shoe care, hair care products, diagnostics reagent and equipments, and other consumer products; the manufacturing and trading of pharmaceuticals and cosmetics; the operation of promotional activities, wharf clearing activities, hotel, food and beverage businesses, and the provision of transport services.

Mergers & acquisitions

There are no recent mergers or acquisitions for J L Morison Sons & Jones (Ceylon) PLC.
Data delayed at least 20 minutes, as of Jul 31 2014 08:03 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Biokhimik OAO (P)
4.98bn-264.19m1.49bn1.78k--0.6025--0.2994-0.0205-0.02050.38680.19230.94682.332.69---5.23323.57-10.21413.5713.1217.68-5.52711.670.7356-0.94870.3621---1.39543.93-85.989---25.8607--
Krasfarma OAO (P)
5.31bn91.58m2.01bn551------0.37890.54890.548931.8419.430.90033.071.81--1.550.27722.290.277241.5045.481.720.24821.716.470.00--7.408.96347.44---0.4357--
STAR Pharmaceutical Limited
1.90bn142.18m1.83bn27712.890.8546.170.96450.00580.00580.07780.08780.52562.6122.05--3.50-18.96235.08-18.962340.4934.946.66-36.68161.2957.040.00--0.6263-5.6642103.08--19.61--
UMeWorld Ltd
39.06m-133.21m2.32bn34------59.36-0.0115-0.01150.0034-0.00480.0261--2.208,823.53-8.7492-10.4284-9.4456-10.428498.05---335.7933-97.3347---12.1731.27--355.8350.95-201.3844--15.46--
Unipharm AD Sofia
1.50bn64.79m1.63bn25825.171.096.851.080.12120.12122.812.800.80663.205.12--3.476.483.906.4851.1547.384.316.372.39--0.1196--2.17-2.038784.52-13.8052.96--
Bulgarska Roza-Sevtopolis AD Kazanlak
1.93bn263.81m1.88bn2757.130.88875.220.97350.24530.24531.801.970.83416.758.40--11.385.7812.265.7832.8032.4213.657.833.0741.390.0765--39.8910.57233.7118.42-39.5183--
DIOD OAO
4.17bn-574.26m1.36bn----0.229--0.3267-1.7132-1.713212.4317.730.38720.60491.76---5.34643.86-6.62233.8664.8556.11-13.80716.571.451.330.3383---1.176-8.0446-1,257.461---51.2677--
NatureWise Biotech & Medicals Corp
282.78m-52.16m2.23bn52--2.45--7.87-0.5625-0.56253.059.810.28081.2013.10---5.1792-1.7971-5.5756-1.797145.7763.99-18.4469-4.369112.57--0.00---21.841813.1530.09---16.7279--
Jagsonpal Pharmaceuticals Ltd
3.49bn30.59m1.47bn--47.990.693714.870.42040.54290.542961.9637.551.052.643.70--0.92256.001.386.0046.4346.210.87624.091.171.270.25418.49-5.69332.09-75.4224-9.8385--37.97
Brooks Laboratories Ltd
1.91bn105.71m1.47bn21613.93--11.910.77153.043.0454.83------------13.62--13.6229.8925.115.5411.12------3.1942.8623.25-19.149714.82-20.9092--
Themis Medicare Ltd
----2.01bn-----------------------------1.6315---1.6315--24.55---1.4012--------10.09-6.152785.30---27.7897--
J.L.Morison, Sons & Jones (Ceylon) Ltd.
3.08bn156.09m2.02bn--13.541.0910.540.655820.6720.67407.61256.911.173.384.63--5.959.607.549.6026.6825.235.075.251.85--0.08088.821.8610.62-28.247915.153.79--
KM R&C Co Ltd
----2.02bn16---------------------------87.9693---87.9693--6.91---47.581---------46.902---173.398------
Mustika Ratu Tbk PT
5.05bn310.99m1.80bn2.66k5.790.40619.290.356564.6264.621,049.23921.050.99892.862.46168,444,2006.157.457.007.4556.2856.066.166.695.36--0.022718.8812.7712.6910.3522.5416.7338.49
Cuu Long Pharmaceutical Joint Stock Corp
4.29bn232.74m1.79bn9417.711.004.790.41813,827.663,827.6670,558.2829,406.551.102.953.23752,952,5005.985.4113.445.4132.6227.335.422.840.76173.180.4657--10.257.2758.13-8.0618.86--
S.P.M Corp
2.95bn167.81m1.93bn23411.480.45697.570.65371,986.851,986.8534,882.1849,904.110.41937.321.062,052,437,0002.39--3.45--20.78--5.70--2.512.430.1726--2.59---72.9614------
Data as of Jul 31 2014. Currency figures normalised to J L Morison Sons & Jones (Ceylon) PLC's reporting currency: Sri Lankan Rupee LKR.
Data delayed at least 20 minutes, as of Jul 31 2014 11:45 BST.

Institutional shareholders

There are no institutional shareholders for J L Morison Sons & Jones (Ceylon) PLC.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.